Dr. Roshy Pakdaman serves as the Vice President of Global Product Development at AstraZeneca, where she plays a pivotal role in overseeing the comprehensive development of innovative pharmaceutical products. Her leadership encompasses a diverse portfolio that includes Oral Product Development (OPD), New Modalities Product Development...
Dr. Roshy Pakdaman serves as the Vice President of Global Product Development at AstraZeneca, where she plays a pivotal role in overseeing the comprehensive development of innovative pharmaceutical products. Her leadership encompasses a diverse portfolio that includes Oral Product Development (OPD), New Modalities Product Development (NMPD), and Inhalation Product Development (IPD). With a strong emphasis on advancing drug delivery systems, Roshy’s expertise in solid dispersion techniques—such as spray drying and hot melt extrusion—enables her team to optimize formulations for enhanced bioavailability and patient compliance.
Under her guidance, AstraZeneca is at the forefront of developing new chemical entities (NCEs) through a meticulous process that includes lead optimization, preformulation, and form selection. Roshy’s extensive experience in solid oral dosage forms and semi-solid dosage forms allows her to navigate the complexities of formulation development and process optimization effectively. Her strategic oversight ensures that clinical packaging, process tech transfers, scale-up, and process validation are executed with precision, ultimately driving the successful transition of products from the lab to the market.
Roshy’s commitment to innovation is further exemplified by her collaborative approach, fostering cross-functional partnerships that enhance drug discovery efforts. Her proficiency in analytical techniques, including HPLC and chromatography, complements her formulation expertise, allowing her to address challenges in drug development with a data-driven mindset. As a leader in the pharmaceutical industry, Roshy Pakdaman continues to shape the future of product development at AstraZeneca, ensuring that cutting-edge therapies reach patients in need.
